Unusual presentation of recurrent papillary thyroid microcarcinoma with neck muscles and skin dissemination
- 50 Downloads
Papillary thyroid microcarcinoma is commonly considered to have a good prognosis. We report the case of a 47-year-old male patient, who was referred to our Institution for a papillary thyroid microcarcinoma infiltrating perithyroidal fibroadipose tissue, treated in 2006 with surgery and in 2007 with 131I-therapy (3700 MBq). He was followed up between 2007 and 2017 and was free of disease based on serum Tg and ultrasonography; then, suddenly, some pimple-like neck skin lesions appeared that were not responsive to topical therapy.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All diagnostic and therapeutic procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards.
Informed consent was obtained from the individual participants included in the study.
- 1.Na SJ, Yoo IR, JH O et al (2012) Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med 26:26–34CrossRefGoogle Scholar
- 2.Ozkan E, Aras G, Kucuk NO (2013) Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin Nucl Med 38:326–331CrossRefGoogle Scholar
- 3.Vural GU, Akkas BE, Ercakmak N et al (2012) Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 37:953–959CrossRefGoogle Scholar